Fentanyl Ethypharm
Potent synthetic opioid analgesic – solution for injection 50 micrograms/ml
Quick Facts About Fentanyl Ethypharm
Key Takeaways About Fentanyl Ethypharm
- Hospital use only: Fentanyl Ethypharm is administered exclusively by trained healthcare professionals in monitored clinical environments with resuscitation equipment available
- Extremely potent opioid: Approximately 50–100 times more potent than morphine; even small dosing errors can cause life-threatening respiratory depression
- Rapid onset, short duration: IV fentanyl works within 1–2 minutes with peak effect at 3–5 minutes, making it ideal for procedural analgesia and anesthesia
- Respiratory depression is the primary risk: All patients receiving fentanyl must have continuous monitoring of respiratory rate, oxygen saturation, and consciousness level
- Controlled substance: Classified as Schedule II (US) / Class A (UK) due to high potential for dependence, tolerance, and misuse
What Is Fentanyl Ethypharm and What Is It Used For?
Fentanyl Ethypharm is a potent synthetic opioid analgesic containing fentanyl citrate at a concentration of 50 micrograms per milliliter. It is used in hospitals for analgesia during surgical procedures, as a component of general anesthesia, and for management of severe acute pain in monitored settings. Fentanyl acts on mu-opioid receptors in the central nervous system to produce powerful pain relief.
Fentanyl was first synthesized in 1960 by Paul Janssen and has since become one of the most widely used opioid analgesics in modern medicine. Fentanyl Ethypharm is a branded formulation manufactured by Ethypharm, available as a sterile solution for injection. It belongs to the phenylpiperidine class of synthetic opioids and is characterized by its rapid onset of action, high potency, and relatively short duration of effect compared to morphine.
The primary clinical indications for Fentanyl Ethypharm include use as an analgesic supplement to general anesthesia, induction and maintenance of general anesthesia in combination with other agents (such as oxygen and a muscle relaxant in a technique known as neuroleptanalgesia or neuroleptanesthesia), and management of severe pain requiring opioid analgesia in patients who are adequately monitored. It may also be used for epidural analgesia during labor and postoperative pain management.
Fentanyl exerts its pharmacological effects primarily by binding to mu-opioid receptors (MOR) in the brain, spinal cord, and peripheral tissues. This binding activates descending inhibitory pain pathways, reduces the transmission of pain signals, and alters the perception of and emotional response to pain. The drug also produces sedation, euphoria, and respiratory depression as part of its central nervous system effects.
Fentanyl is approximately 50 to 100 times more potent than morphine and roughly 50 times more potent than heroin on a weight-for-weight basis. This extreme potency means that therapeutic doses are measured in micrograms rather than milligrams. The high lipophilicity of fentanyl allows it to cross the blood-brain barrier rapidly, explaining its fast onset of action when given intravenously.
Pharmacokinetics
When administered intravenously, fentanyl has an onset of action within 1 to 2 minutes, with peak analgesic effect occurring at approximately 3 to 5 minutes. The duration of a single intravenous bolus dose is typically 30 to 60 minutes due to rapid redistribution from the brain to other tissues (particularly fat and muscle). However, with repeated doses or continuous infusion, the context-sensitive half-time increases significantly as tissue stores become saturated.
Fentanyl is highly protein-bound (approximately 80–85%), primarily to alpha-1 acid glycoprotein and albumin. It is extensively metabolized in the liver, primarily by the cytochrome P450 3A4 (CYP3A4) enzyme system, to the inactive metabolite norfentanyl. The elimination half-life following intravenous administration is approximately 3 to 4 hours, although terminal elimination half-life may be longer (up to 12 hours) due to slow release from tissue compartments.
Clinical uses in detail
In surgical settings, fentanyl is commonly used as a co-induction agent alongside propofol or thiopentone to blunt the hemodynamic response to laryngoscopy and intubation. It is also used for maintenance of analgesia during surgery, either as intermittent boluses or as a continuous infusion. In cardiac surgery, higher doses of fentanyl (up to 50–100 mcg/kg) may be used as a primary anesthetic agent because it provides excellent hemodynamic stability with minimal myocardial depression.
For postoperative pain management, fentanyl may be administered via patient-controlled analgesia (PCA) devices, epidural infusions (often in combination with local anesthetics such as bupivacaine), or as part of multimodal analgesia protocols. The World Health Organization includes fentanyl on its Model List of Essential Medicines, recognizing its importance in modern healthcare.
What Should You Know Before Taking Fentanyl Ethypharm?
Fentanyl Ethypharm must not be used in patients with severe respiratory depression, acute or severe bronchial asthma without monitoring, known hypersensitivity to fentanyl, or concurrent use of monoamine oxidase inhibitors (MAOIs). Special caution is required in elderly patients, those with hepatic or renal impairment, head injuries, or chronic obstructive pulmonary disease.
Contraindications
Fentanyl Ethypharm is contraindicated in several important clinical scenarios. Healthcare professionals must assess patients thoroughly before administration to identify any conditions that would make fentanyl use inappropriate or dangerous. The following are absolute contraindications to the use of Fentanyl Ethypharm:
- Known hypersensitivity to fentanyl, other opioid analgesics, or any of the excipients in the formulation
- Severe respiratory depression or severe obstructive airway conditions in unmonitored settings without resuscitation equipment
- Concurrent use of MAO inhibitors or within 14 days of discontinuation, due to the risk of serotonin syndrome and unpredictable potentiation of opioid effects
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
Warnings and Precautions
Even in patients without absolute contraindications, fentanyl requires careful clinical judgment and dose adjustment in numerous situations. Respiratory depression is the most serious adverse effect of fentanyl and the primary cause of opioid-related fatalities. It is dose-dependent and can occur at any point during therapy, particularly during initiation or dose escalation. All patients receiving fentanyl must have continuous monitoring of respiratory rate, pulse oximetry, level of consciousness, and blood pressure.
Chest wall rigidity (also known as wooden chest syndrome) is a recognized complication of rapid intravenous fentanyl administration, particularly at higher doses. This rigidity can severely impair ventilation and may require treatment with neuromuscular blocking agents and assisted ventilation. To minimize this risk, fentanyl should be administered slowly, and muscle relaxants should be readily available.
Special caution is warranted in the following patient populations:
- Elderly patients: Increased sensitivity to opioids due to reduced hepatic blood flow, decreased protein binding, and altered pharmacokinetics. Dose reduction of 30–50% is typically recommended
- Hepatic impairment: Fentanyl is extensively metabolized by the liver; impaired hepatic function can lead to prolonged and enhanced drug effects
- Renal impairment: While fentanyl itself is not significantly renally eliminated, accumulation of metabolites may occur
- Head injury or raised intracranial pressure: Opioids can increase intracranial pressure and may obscure the clinical course of patients with head injuries
- Chronic obstructive pulmonary disease (COPD): Patients with pre-existing respiratory compromise are at increased risk of respiratory depression
- Cardiovascular instability: Fentanyl can cause bradycardia and hypotension, particularly in hypovolemic patients
- Hypothyroidism: Enhanced sensitivity to opioid effects
- Myasthenia gravis: Risk of exacerbated muscle weakness and respiratory compromise
Respiratory depression is the chief hazard of fentanyl. It can occur at any dose, particularly in opioid-naive patients, elderly patients, or when combined with other CNS depressants. Facilities administering fentanyl must have immediate access to an opioid antagonist (naloxone), bag-valve-mask ventilation equipment, endotracheal intubation equipment, and oxygen.
Pregnancy and Breastfeeding
Fentanyl crosses the placental barrier and should be used during pregnancy only when the potential benefit justifies the potential risk to the fetus. Animal studies have shown reproductive toxicity at high doses. The use of fentanyl during labor may cause respiratory depression in the newborn, and resuscitation facilities for the neonate must be available. Naloxone should be readily accessible for reversal of neonatal respiratory depression.
Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS), which may be life-threatening if not recognized and treated promptly. Symptoms in the neonate include irritability, hyperactivity, abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, and failure to gain weight.
Fentanyl is excreted in breast milk. A decision should be made whether to discontinue breastfeeding or to discontinue or abstain from fentanyl therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. Breastfeeding is generally not recommended for 24 hours following fentanyl administration.
How Does Fentanyl Ethypharm Interact with Other Drugs?
Fentanyl has clinically significant interactions with numerous drug classes. The most dangerous interactions involve other CNS depressants (benzodiazepines, alcohol, other opioids), MAO inhibitors, CYP3A4 inhibitors (which increase fentanyl levels), and serotonergic agents (risk of serotonin syndrome). All concurrent medications must be carefully reviewed before fentanyl administration.
Drug interactions with fentanyl can be pharmacokinetic (affecting absorption, distribution, metabolism, or elimination) or pharmacodynamic (additive or synergistic effects at receptor level). Given fentanyl's narrow therapeutic window and extreme potency, even modest changes in plasma concentrations or receptor-level effects can have clinically significant consequences, including fatal respiratory depression.
| Drug / Drug Class | Type of Interaction | Clinical Effect | Recommendation |
|---|---|---|---|
| Benzodiazepines (midazolam, diazepam) | Pharmacodynamic (additive CNS depression) | Profound sedation, respiratory depression, coma, death | Use lowest effective doses; enhanced monitoring required |
| MAO inhibitors (phenelzine, tranylcypromine) | Pharmacodynamic (unpredictable potentiation) | Serotonin syndrome, severe respiratory depression, hypotension, coma | Contraindicated. Wait 14 days after MAOI discontinuation |
| CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) | Pharmacokinetic (decreased metabolism) | Increased fentanyl plasma levels, prolonged duration, enhanced respiratory depression | Reduce fentanyl dose; increase monitoring frequency |
| CYP3A4 inducers (rifampicin, carbamazepine, phenytoin) | Pharmacokinetic (increased metabolism) | Reduced fentanyl efficacy, potential withdrawal symptoms | May need increased fentanyl dose; monitor analgesic effect |
| Serotonergic agents (SSRIs, SNRIs, triptans, tramadol) | Pharmacodynamic (serotonin accumulation) | Serotonin syndrome (agitation, hyperthermia, rigidity, myoclonus) | Monitor for serotonin syndrome; consider alternative agents |
| Other opioids (morphine, remifentanil) | Pharmacodynamic (additive opioid effects) | Enhanced respiratory depression, sedation, hypotension | Adjust doses carefully; continuous respiratory monitoring |
| Alcohol / sedatives | Pharmacodynamic (additive CNS depression) | Fatal respiratory depression even at low doses | Patients must avoid alcohol; assess recent intake |
Major Interactions
The FDA and EMA have issued boxed warnings (Black Box Warning) regarding the concomitant use of opioids and benzodiazepines, as this combination significantly increases the risk of fatal respiratory depression. When co-administration is clinically necessary (as is common in anesthesia), the lowest effective doses should be used with careful titration and continuous monitoring. The risk is further amplified when other CNS depressants, including alcohol, are present.
The interaction between fentanyl and MAO inhibitors deserves particular attention. MAOIs can unpredictably potentiate opioid effects through multiple mechanisms, including enhanced serotonergic transmission and impaired opioid metabolism. Cases of severe hypertension, hyperthermia, seizures, and death have been reported. Fentanyl must not be administered to patients currently taking MAOIs or within 14 days of their discontinuation.
Minor Interactions
Certain medications may have less clinically significant but still relevant interactions with fentanyl. Anticholinergic drugs may increase the risk of urinary retention and severe constipation, potentially leading to paralytic ileus. Diuretics may reduce the efficacy of fentanyl through altered fluid and electrolyte status. Mixed agonist-antagonist opioids (such as buprenorphine, nalbuphine, or pentazocine) may reduce the analgesic effect of fentanyl and may precipitate withdrawal symptoms in opioid-dependent patients.
What Is the Correct Dosage of Fentanyl Ethypharm?
Fentanyl Ethypharm dosing must be individualized based on the clinical indication, patient age, body weight, physical status, concurrent medications, and type of procedure. For analgesia during surgery, typical adult IV doses range from 1 to 2 mcg/kg for minor procedures to 20–50 mcg/kg for major cardiac surgery. Dosing must always be titrated to clinical effect by trained professionals.
Dosing of Fentanyl Ethypharm is highly individualized and depends on multiple factors. Unlike many other medications, fentanyl does not have simple fixed-dose regimens. All doses must be carefully calculated and administered by qualified healthcare professionals who can manage the respiratory and cardiovascular effects of the drug. The following dosing guidelines are general recommendations and must be adapted to individual patient needs.
Adults
Analgesic Supplement to General Anesthesia
Low dose: 1–2 mcg/kg IV for minor surgical procedures. Provides modest analgesia for approximately 30–60 minutes.
Moderate dose: 2–20 mcg/kg IV for moderate to major surgical procedures. Additional increments of 25–50 mcg may be given as needed.
High dose: 20–50 mcg/kg IV for major cardiac or thoracic surgery where prolonged hemodynamic stability is required. Used with oxygen and a neuromuscular blocker.
Sole Anesthetic Agent
Dose: 50–100 mcg/kg IV with oxygen and a neuromuscular blocking agent. Used primarily in open cardiac surgery and certain neurosurgical procedures where avoidance of myocardial depressant agents is essential.
Epidural Analgesia
Dose: 50–100 mcg as a bolus, often combined with a local anesthetic (e.g., bupivacaine 0.125%). Continuous epidural infusion typically 25–100 mcg/hour.
Children
Pediatric dosing of fentanyl requires particular care due to differences in pharmacokinetics and increased sensitivity in neonates and infants. Neonates have reduced hepatic metabolism and protein binding, leading to higher free drug concentrations and prolonged effects.
Pediatric Analgesia (Children over 2 years)
Dose: 1–3 mcg/kg IV for analgesic supplement to anesthesia. Additional increments of 1 mcg/kg may be given as required.
Neonates and infants: Reduced doses are essential. Typically 1–2 mcg/kg IV with careful titration and extended monitoring. Neonates may require up to 50% dose reduction compared to older children.
Elderly
Elderly patients (generally over 65 years) should receive reduced initial doses of fentanyl, typically 30–50% lower than standard adult doses. Age-related changes in pharmacokinetics include reduced hepatic blood flow, decreased lean body mass, increased body fat percentage (affecting distribution), and reduced albumin levels. These changes result in higher peak plasma concentrations, prolonged duration of action, and increased sensitivity to respiratory depression. The dose should be carefully titrated based on clinical response, and the interval between incremental doses should be extended.
Missed Dose
The concept of a missed dose does not apply to Fentanyl Ethypharm in the traditional sense, as it is administered by healthcare professionals in clinical settings rather than self-administered on a schedule. Dosing decisions are made in real-time based on the patient's clinical status, pain level, respiratory function, and hemodynamic parameters. If an inadequate analgesic effect is observed, additional doses may be administered after careful assessment.
Overdose
Fentanyl overdose is a medical emergency that requires immediate intervention. The clinical presentation of fentanyl overdose includes severe respiratory depression (respiratory rate below 8 breaths per minute or apnea), pinpoint pupils (miosis), loss of consciousness, cyanosis, cardiovascular collapse, and cardiac arrest. Due to fentanyl's extreme potency, the margin between a therapeutic dose and a lethal dose can be narrow, particularly in opioid-naive individuals.
The primary treatment for fentanyl overdose is naloxone (Narcan), an opioid antagonist. Because fentanyl's duration of action may exceed that of naloxone (which typically lasts 30–90 minutes), repeated doses or a continuous naloxone infusion may be necessary. Initial adult dose: 0.4–2 mg IV, repeated every 2–3 minutes as needed. Maintain assisted ventilation with 100% oxygen until spontaneous respiration is restored. Continuous cardiorespiratory monitoring is essential for at least 24 hours following severe overdose.
What Are the Side Effects of Fentanyl Ethypharm?
The most common side effects of Fentanyl Ethypharm include nausea, vomiting, muscle rigidity, respiratory depression, bradycardia, and hypotension. Respiratory depression is the most serious side effect and can be fatal. Side effects are generally dose-dependent and most are manageable in a monitored clinical setting with appropriate interventions available.
Like all opioid analgesics, fentanyl produces a range of pharmacological effects beyond analgesia. While many of these are predictable extensions of its opioid agonist activity, the severity and clinical significance depend on the dose administered, the rate of administration, the patient's underlying health status, and concurrent medications. The following frequency categories are based on published clinical data, post-marketing surveillance reports, and international prescribing information.
Very Common
- Nausea – particularly during recovery from anesthesia
- Vomiting – related to opioid stimulation of the chemoreceptor trigger zone
- Muscle rigidity – especially truncal and chest wall rigidity with rapid IV injection
Common
- Respiratory depression – dose-dependent; most serious adverse effect
- Bradycardia – due to vagal stimulation; may require atropine
- Hypotension – particularly in hypovolemic patients or with concurrent vasodilators
- Drowsiness and sedation – may persist into the postoperative period
- Dizziness – related to CNS depression and orthostatic changes
- Pruritus (itching) – particularly with epidural or intrathecal use, related to histamine release
- Constipation – due to reduced gastrointestinal motility
- Urinary retention – more common with neuraxial administration
Uncommon
- Laryngospasm – involuntary closure of the vocal cords
- Bronchospasm – particularly in patients with reactive airway disease
- Euphoria or dysphoria – mood alterations due to CNS opioid effects
- Visual disturbances – blurred vision during recovery
- Postoperative confusion or delirium – more common in elderly patients
- Allergic dermatitis – skin reactions at injection site or generalized
Rare
- Anaphylaxis – severe allergic reaction requiring immediate treatment
- Seizures – particularly at very high doses or in susceptible patients
- Cardiac arrest – typically secondary to severe respiratory depression or bradycardia
- Serotonin syndrome – when combined with serotonergic agents
- Adrenal insufficiency – with prolonged or repeated use
It is important to note that many of these side effects are manageable in the controlled clinical environment where Fentanyl Ethypharm is typically administered. Respiratory depression can be reversed with naloxone, bradycardia with atropine or glycopyrrolate, muscle rigidity with neuromuscular blocking agents, and nausea/vomiting with antiemetic agents (ondansetron, droperidol). The key to safe fentanyl use is vigilant monitoring and the immediate availability of reversal agents and resuscitation equipment.
Long-term effects and dependence
Although Fentanyl Ethypharm is primarily used for acute indications, repeated exposure to fentanyl can lead to the development of tolerance (requiring higher doses for the same effect), physical dependence (withdrawal symptoms upon cessation), and in some cases, opioid use disorder. Physical dependence can develop after as few as several days of continuous use. Healthcare providers should be aware of these risks, particularly in patients requiring prolonged intensive care unit stays with fentanyl infusions.
How Should You Store Fentanyl Ethypharm?
Fentanyl Ethypharm should be stored below 25°C (77°F), protected from light and freezing. As a controlled substance, it must be kept in a locked, secure location with documented chain of custody. Unused portions must be disposed of in accordance with local controlled substance regulations. Do not use after the expiration date.
Proper storage of Fentanyl Ethypharm is critical both for maintaining drug stability and for regulatory compliance as a controlled substance. The solution for injection should be stored at temperatures not exceeding 25°C (77°F). It should be protected from light, as prolonged exposure to light can degrade the active substance. The product must not be frozen.
As a Schedule II controlled substance (or equivalent classification depending on jurisdiction), Fentanyl Ethypharm must be stored in a locked, secure cabinet or safe within the pharmacy or clinical area. Access must be restricted to authorized personnel only, and all dispensing, administration, and disposal of fentanyl must be documented in a controlled substance register. Discrepancies in fentanyl accounting must be immediately reported and investigated.
Once an ampoule or vial has been opened, the product should be used immediately. Any unused portion should not be stored for later use and must be destroyed according to institutional policies and local regulatory requirements for controlled substance disposal. This typically involves witnessed destruction and documentation by two qualified healthcare professionals.
Fentanyl Ethypharm should not be used after the expiration date printed on the packaging. The solution should be visually inspected before use – it should be clear and colorless. Do not use if the solution is discolored, contains particulate matter, or if the container appears damaged.
What Does Fentanyl Ethypharm Contain?
Fentanyl Ethypharm contains fentanyl as the active substance (in the form of fentanyl citrate), equivalent to 50 micrograms of fentanyl per milliliter of solution. Excipients include sodium chloride for isotonicity and water for injections as the solvent. The pH may be adjusted with sodium hydroxide and/or hydrochloric acid.
Active ingredient
The active pharmaceutical ingredient in Fentanyl Ethypharm is fentanyl citrate. Fentanyl citrate is the salt form of fentanyl, which provides improved water solubility suitable for parenteral formulations. Each milliliter of solution contains fentanyl citrate equivalent to 50 micrograms of fentanyl base. Ampoules are typically available in 2 ml (100 mcg) and 10 ml (500 mcg) presentations.
Fentanyl (chemical name: N-(1-phenethyl-4-piperidinyl)-N-phenylpropanamide) has a molecular weight of 336.47 g/mol (as fentanyl base) or 528.59 g/mol (as fentanyl citrate). It is a white crystalline powder that is sparingly soluble in water and freely soluble in organic solvents.
Excipients (inactive ingredients)
- Sodium chloride: Added to achieve isotonicity with physiological fluids, ensuring compatibility with intravenous administration
- Water for injections: The vehicle/solvent, meeting pharmacopoeial standards for sterility and purity
- Sodium hydroxide and/or hydrochloric acid: Used for pH adjustment to approximately 4.0–7.5, ensuring stability and compatibility
The formulation is free from preservatives, antimicrobial agents, and latex. The product is designed for single-use administration, and any unused portion should be discarded. Healthcare professionals should note that the formulation is compatible with commonly used intravenous fluids (0.9% sodium chloride, 5% dextrose) when dilution is required.
Frequently Asked Questions About Fentanyl Ethypharm
Medical References and Sources
This article is based on current medical research, regulatory prescribing information, and international guidelines. All claims are supported by scientific evidence from peer-reviewed sources.
- European Medicines Agency (EMA). "Summary of Product Characteristics: Fentanyl citrate solution for injection." European regulatory prescribing information for fentanyl injection products.
- U.S. Food and Drug Administration (FDA). "SUBLIMAZE (fentanyl citrate) injection - Prescribing Information." Complete US prescribing information including Black Box Warning for opioid-benzodiazepine co-use.
- World Health Organization (WHO) (2023). "Model List of Essential Medicines, 23rd List." Fentanyl included as an essential medicine for anesthesia and pain management.
- British National Formulary (BNF). "Fentanyl - Indications, Dose, Contra-indications, Side-effects." UK national prescribing reference for fentanyl formulations.
- Peng PWH, Sandler AN. (1999). "A Review of the Use of Fentanyl Analgesia in the Management of Acute Pain in Adults." Anesthesiology. 90(2):576-599. Comprehensive review of fentanyl pharmacology and clinical applications in acute pain.
- Miller RD, et al. (2020). "Miller's Anesthesia, 9th Edition." Elsevier. Chapter 24: Opioid Agonists and Antagonists. Definitive textbook reference for opioid pharmacology in anesthesiology.
- Dowell D, et al. (2022). "CDC Clinical Practice Guideline for Prescribing Opioids for Pain." MMWR Recomm Rep. 71(No. RR-3):1-95. Updated CDC guidelines for opioid prescribing, risk assessment, and monitoring.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Information is derived from regulatory prescribing information, systematic reviews, and established pharmacological references representing the highest quality of available evidence.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against regulatory prescribing information, peer-reviewed sources, and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research or regulatory changes emerge.
Corrections Policy
Any errors are corrected immediately with transparent changelog. Read more
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in anesthesiology, pain medicine, pharmacology, and emergency medicine.